Mesoblast (MEOBF) Common Equity (2014 - 2026)

Mesoblast has disclosed Common Equity across 13 years of filings, most recently posting $568.4 million for Q2 2026.

• In Q2 2026, Common Equity fell 4.86% year-over-year to $568.4 million; the TTM figure through Jun 2026 stood at $568.4 million (down 4.86% YoY), while the FY2026 annual figure was $568.4 million, down 4.86% from the prior year.
• Common Equity came in at $568.4 million for Q2 2026 at Mesoblast, down from $574.7 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $597.4 million in Q2 2025 to a low of $461.3 million in Q4 2024.
• Average Common Equity over 5 years is $517.7 million, with a median of $505.3 million recorded in 2023.
• Year-over-year, Common Equity retreated 14.51% in 2022 and gained 24.59% in 2025.
• Over 5 years, Common Equity stood at $500.0 million in 2022, then advanced by 1.75% to $508.7 million in 2023, then dropped by 9.33% to $461.3 million in 2024, then grew by 24.59% to $574.7 million in 2025, then decreased by 1.09% to $568.4 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $568.4 million in Q2 2026, $574.7 million in Q4 2025, and $597.4 million in Q2 2025.